Dr. Portman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
250 E Broad St
Suite 250
Columbus, OH 43215Phone+1 614-864-4919
Education & Training
Ohio State University/Mt Carmel HospitalResidency, Obstetrics and Gynecology, 1990 - 1994- Ohio State University College of MedicineClass of 1990
Certifications & Licensure
OH State Medical License 1991 - 2026
Publications & Presentations
PubMed
- Effects of Lasofoxifene Versus Fulvestrant on Vaginal and Vulvar Symptoms in Patients With ESR1-Mutated, ER+/HER2-, Metastatic Breast Cancer From the ELAINE 1 Study.Shari B Goldfarb, Sarah L Sammons, Jane L Meisel, Timothy J Pluard, Simon N Jenkins
Clinical Breast Cancer. 2024-12-13 - 1 citationsOral lasofoxifene's effects on moderate to severe vaginal atrophy in postmenopausal women: two phase 3, randomized, controlled trials.Risa Kagan, James A Simon, Steven R Goldstein, Barry S Komm, Simon N Jenkins
Menopause. 2024-06-01 - Variability in Contraceptive Clinical Trial Design and the Challenges in Making Comparisons Across Trials.David Portman, David L. Eisenberg, Patty Cason, Brandon Howard
Advances in Therapy. 2021-09-23
Press Mentions
Sermonix Pharmaceuticals Completes Enrollment of Phase 2 I-SPY 2 Arm Evaluating Lasofoxifene in Neoadjuvant Breast Cancer SettingAugust 27th, 2024- Phase 3 Trial of Fablyn plus Verzinio for Metastatic Breast Cancer Initiates RegistrationMarch 20th, 2023
- Sermonix's Lasofoxifene Improves Vaginal/Vulvar Symptoms Relative to Fulvestrant in ELAINE 1 Study of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 MutationMarch 6th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
